{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-021496","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2026-05-15T11:50:30+00:00","discovered_at":"2026-05-15T11:55:00.243573+00:00","generated_at":"2026-05-15T11:55:07.290659+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Galectin Q1 net loss narrows to $5.1M; belapectin data at EASL, FDA meeting ahead","bullets":["Net loss of $5.1M ($0.08 per share) vs $9.6M ($0.15) in Q1 2025; R&D expense fell to $2.2M from $6.5M.","Cash $14.1M as of Mar 31, plus $10M credit line from chairman; company expects to fund ops through May 2027.","Belapectin 2 mg/kg showed statistically significant liver stiffness reductions (FibroScan) at Weeks 26, 52, 78 in NAVIGATE trial.","Oral/poster presentations at EASL Congress May 28-30; Type-C FDA meeting scheduled for Q2 2026.","Board appointed Dr. Henry Brem in Jan 2026; KOL event on MASH cirrhosis held in March 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-021496","json":"https://secwatch.observer/filing/0001140361-26-021496.json","markdown":"https://secwatch.observer/filing/0001140361-26-021496.md","text":"https://secwatch.observer/filing/0001140361-26-021496.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036126021496/0001140361-26-021496-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036126021496/ef20073003_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:55:07.290659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9cad2f7d0d653c1fa10efdebc67b018dc7f13fc3","claim":"GALECTIN THERAPEUTICS INC reported three months ended March 31, 2026 results: net income $5.1 million, or ($0.08) per share, EPS ($0.08) per share.","evidence_excerpt":"For the quarter ended quarter ended March 31, 2026, the Company reported a net loss applicable to common stockholders of $5.1 million, or ($0.08) per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036126021496/0001140361-26-021496-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2026"},{"label":"Net income","value":"$5.1 million, or ($0.08) per share"},{"label":"EPS","value":"($0.08) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}